Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Syndax Pharmaceuticals, Inc.

https://www.syndax.com/

Latest From Syndax Pharmaceuticals, Inc.

Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence

Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry. 

Commercial Ophthalmic

Finance Watch: Public Biopharma Firms Take Advantage Of Relative Upswing

Public Company Edition: Prometheus brought in $500m from a follow-on offering after reporting positive mid-stage results for its TL1A inhibitor. Even Novavax, struggling to make money from its COVID-19 vaccine, raised cash in dual offerings, but its valuation dropped significantly afterward.

Financing Business Strategies

Spain's Oryzon Bucks Trend To Seek NASDAQ Listing

The year to date has been a depressing period for initial public offerings, especially in Europe, but the Madrid-based epigenetics specialist is evaluating whether to head west and list in the US.


Financing Business Strategies

‘The Next Tulip Mania?’ – Fidelity, Gurnet, Biogen Put A Lens To Funding, Valuations

Venture capital funding for biotechs remains aplenty even as listed companies’ stock prices drop. Biogen’s Papadopoulos, Fidelity’s Kaul and Gurnet’s and ex-Sanofi Viehbacher deliberate on whether there is a valuation disconnect and if this is the next "tulip mania."

Commercial Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register